The composition includes a cyclic, unsaturated compound, preferably a polyphenol derivative. It reduces the synthesis of melanin by inhibiting the activity and expression levels of tyrosinase and related proteins, thereby preventing and limiting the content and distribution of melanin in mammalian skin. It also induces autophagy of melanosome, thereby restricting the synthesis, storage and transfer of melanin from melanocyte to keratinocyte. The dual modes of action allow for the efficacy of the composition at low dosage without causing toxicity to lighten skin and treat disorders associated with hyperpigmentation.

The present invention relates to the production of eriodictyol via bioconversion.

The present invention relates to the production of eriodictyol via bioconversion.

A therapeutic compound has a modified phenolic compound of the general formula (I) wherein at least one of R, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is an electrophilic group chosen from halogen, aldehyde, haloalkane, alkene, butyryl, flurophenol, sulfonamide, flurophenol sulfoxide and the remaining R, R.sub.1, R.sub.2, R.sub.3, and R.sub.4 is are each independently hydrogen, a hydroxyl group, an alkoxy group, a rutinosyl group, a carboxyl group, chromone, benzopyran, a rhamnosyl group, a substituted alkoxy group or a substituted acyloxy group wherein the substituent is chosen from hydroxyl, alkoxy, aryloxy, phenyl, halogen, and amido group. The compound can be used in a therapeutic treatment of inflammatory related diseases and condition. ##STR00001##

Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.

Provided is a medical compound including a synthetic flavone derivative, according to the formula (I) with allotment in position C-3 of a group as shown below:

##STR00001##

wherein at least two of R.sub.2-R.sub.6 are H, and the remaining are independently selected from: H, OH, R.sub.1, OR.sub.1, NO.sub.2, NH.sub.2, NHR.sub.1, F, Cl, Br, I, where R.sub.1 is a radical.

Polymeric materials are described which have a bioflavonoid coating, the bioflavonoid content of the coating comprising at least naringin and neohesperidin. The use of such coated polymeric materials is also described as well as the process for making the coated polymeric materials.

Polymeric materials are described which have a bioflavonoid coating, the bioflavonoid content of the coating comprising at least naringin and neohesperidin. The use of such coated polymeric materials is also described as well as the process for making the coated polymeric materials.

A new analgesic has been developed for T-type calcium channels as therapeutic targets.

The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1):

##STR00001##

wherein
each of R.sup.1 and R.sup.2 independently represents H or OH;
R.sup.3 represents OH;
R.sup.4 represents OH or H;
R.sup.5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms,
or a pharmaceutically acceptable salt or solvate thereof.

The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.

A new analgesic has been developed for T-type calcium channels as therapeutic targets.

The present invention provides a T-type calcium channel inhibitor which is a compound represented by formula (1):

##STR00001##

wherein
each of R.sup.1 and R.sup.2 independently represents H or OH;
R.sup.3 represents OH;
R.sup.4 represents OH or H;
R.sup.5 represents a straight or branched alkyl or cycloalkyl-alkyl group having one to ten carbon atoms or a straight or branched alkenyl or cycloalkyl-alkenyl group having two to ten carbon atoms,
or a pharmaceutically acceptable salt or solvate thereof.

The present invention also provides this T-type calcium channel inhibitor, a medicament containing the T-type calcium channel inhibitor, and a therapeutic or prophylactic agent for a disease having an effective T-type calcium channel inhibitory action.